All In Biotech

Drug Trial Radar · NCT00279045

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Nov 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,426 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,426

Actual

Start

Jan 3, 2000

Primary completion

Jun 1, 2006

Study completion Jun 19, 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • RosiglitazoneDrug

  • glyburideDrug

  • metforminDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from randomization to the primary action point (monotherapy failure).

Locations

490 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Berkeley, California

  • GSK Investigational Site

    Corona, California

  • GSK Investigational Site

    Fair Oaks, California

  • GSK Investigational Site

    Fremont, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fullerton, California

  • GSK Investigational Site

    Greenbrae, California

  • GSK Investigational Site

    Harbor City, California

  • GSK Investigational Site

    Healdsburg, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Loma Linda, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Pasadena, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Santa Rosa, California

  • GSK Investigational Site

    Sunnyvale, California

  • GSK Investigational Site

    Ukiah, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Yorba Linda, California

  • GSK Investigational Site

    Boulder, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Englewood, Colorado

  • GSK Investigational Site

    Longmont, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Jacksonville, Florida

Showing 40 of 490 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.